Chief Data Officer — Specialist-Clinics Portfolio

The mandate

A specialist-clinics portfolio has entered payer negotiations that depend on credible outcomes, pathway utilisation and access evidence. Existing reports reconcile finance, scheduling and clinical data differently, creating disagreement over the same patient population. A Chief Data Officer role has been authorised because no current executive owns clinical meaning, permitted use and adopted data products end to end.

Approximately 575 employees and material partners work across clinics, diagnostics, finance, technology, analytics and customer functions in London and the wider United Kingdom. The CDO owns data strategy, governance, platforms, analytics, data products and responsible advanced analytics, reporting to the Group Chief Executive or nominated sponsor. Clinical, privacy and information-security leaders retain independent decision rights in their domains.

The first product will be a governed payer population. Eligibility, referral, episode, practitioner, outcome and payment data must reconcile through agreed definitions. The CDO will document inclusion, exclusion, time windows and attribution. Differences between contracted members, patients who sought care and completed episodes should remain visible rather than collapsed into a favourable denominator.

Clinical meaning needs named stewardship. A procedure code may not capture indication, complexity or outcome. The CDO will pair data owners with authorised clinical stewards who can define safe interpretation. Data quality issues will be resolved at source where possible, and reports will display known limitations rather than conceal them in methodology notes.

Outcomes require risk adjustment and restraint. Comparing clinics or clinicians without accounting for case mix can distort improvement and damage trust. The data team will make model choices explainable, test sensitivity and prevent ranking where sample size or completeness is inadequate. Statistical confidence should determine what can be concluded.

Payer-mix analysis will connect clinical utilisation, authorisation, tariff and collection. The CDO will build products that show pathway demand and contractual consequence without encouraging inappropriate restriction. A high-cost cohort may indicate unmet coordination needs rather than undesirable patients; interpretation will involve clinical and commercial leaders.

Patient data use needs precise purpose. Information collected for care cannot be assumed available for marketing, research or product development. The CDO will establish lawful basis, consent where required, minimum use, retention and access. De-identification will be assessed against linkage and rare-condition risk, not treated as a universal permission.

The platform roadmap should follow product demand. Current investment includes a lake, separate marts and numerous spreadsheets, but few products have accountable business users. The CDO will define source contracts, lineage, quality thresholds and service ownership, then stop pipelines that support neither a regulatory obligation nor an adopted decision.

Data reconciliation must become observable. When source values arrive late or change, downstream products need version, freshness and impact information. Payer submissions and board measures should be reproducible from retained logic and snapshots. Manual adjustment requires author, reason, approval and expiry.

Advanced analytics will be governed by consequence. Models used for capacity, no-show or pathway prediction can influence access. The CDO will require training-data provenance, performance by relevant cohort, human review and monitoring. A model that improves aggregate accuracy while worsening a vulnerable group's outcome will not pass production review.

Data-product adoption will be measured through changed decisions. A clinic capacity product should show who uses it, which sessions change and whether access improves. Dashboard views are not value. Product owners will carry outcome, user, quality and operating-cost accountability through the lifecycle.

Payer disclosure must be controlled. Contractual reporting rights differ, and small cells can expose patients or commercially sensitive clinician information. The CDO will standardise secure exchange, approval and audit. Requests outside agreement will be evaluated rather than fulfilled informally to preserve a relationship.

The data function needs different talent. Engineers, product managers, analysts and stewards must work with clinics, not operate as a report factory. The CDO will build product teams, develop data literacy among operating leaders and create career paths for technical expertise without forcing every specialist into management.

What you will own

• Payer and pathway data-product strategy.
• Definitions, stewardship, lineage and quality.
• Outcomes, risk adjustment and analytic interpretation.
• Privacy, purpose, consent and secure disclosure.
• Data platform, product lifecycle and adoption.
• Responsible predictive analytics and monitoring.
• Regulatory, payer and board data confidence.
• Data talent, operating model and succession.

The first 12 months

Within 45 days, reconcile one priority payer population, identify conflicting clinical definitions and stop any external report that cannot be reproduced. Establish product owners and stewards.

By month six, release governed payer and capacity products, implement lineage and secure disclosure, and retire redundant reports. Complete cohort testing for any model affecting access.

At twelve months, achieve 98% definition and source-quality conformance for priority payer measures, reduce manual external-report adjustments by 80% and cut reconciliation time by 60%. At least four data products should demonstrate adopted decisions and measurable access or cash outcomes, with no patient data use outside documented purpose and authority.

What the sponsor will examine

• Payer denominators transparent and reproducible.
• Clinical meaning owned by qualified stewards.
• Outcomes interpreted with case-mix limitations.
• Patient purpose governing secondary data use.
• Models tested across relevant cohorts.
• Product value evidenced through operating decisions.

The person

You bring 18–22 years in data leadership, including CDO or substantial portfolio accountability in healthcare, insurance, life sciences or another regulated data environment. Your experience covers clinical semantics, payer data, product management, privacy and advanced analytics deployed into real decisions.

Candidates should demonstrate a contested outcome measure they made trustworthy and a model they limited when subgroup evidence failed. UK data-protection and healthcare exposure are essential. This permanent appointment is onsite in London to embed data teams with clinic and payer decisions.

Compensation and terms

Base compensation is GBP 250,000–340,000 plus annual incentive and long-term participation linked to trusted payer data, adoption, privacy, access outcomes and data leadership. The permanent onsite London role reports to the Group Chief Executive or nominated executive-committee sponsor. The unplanned search is urgent because payer decisions are active.

Confidentiality

The clinics, patients, payers, contracts, models, data definitions and negotiations remain confidential. More information follows conflict review and signed confidentiality. Candidates must not contact providers, insurers or data partners to identify the client.